CY1121380T1 - Γονιδιακη θεραπεια για τη νοσο νιεμann-pick τυπου a - Google Patents
Γονιδιακη θεραπεια για τη νοσο νιεμann-pick τυπου aInfo
- Publication number
- CY1121380T1 CY1121380T1 CY20181101265T CY181101265T CY1121380T1 CY 1121380 T1 CY1121380 T1 CY 1121380T1 CY 20181101265 T CY20181101265 T CY 20181101265T CY 181101265 T CY181101265 T CY 181101265T CY 1121380 T1 CY1121380 T1 CY 1121380T1
- Authority
- CY
- Cyprus
- Prior art keywords
- niemann
- pick type
- gene treatment
- mammalian
- polypeptide
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000002440 hepatic effect Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000005171 mammalian brain Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77162806P | 2006-02-08 | 2006-02-08 | |
| US77236006P | 2006-02-09 | 2006-02-09 | |
| PCT/US2007/003388 WO2007092563A2 (en) | 2006-02-08 | 2007-02-08 | Gene therapy for niemann-pick disease type a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121380T1 true CY1121380T1 (el) | 2020-05-29 |
Family
ID=38345806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101265T CY1121380T1 (el) | 2006-02-08 | 2018-11-28 | Γονιδιακη θεραπεια για τη νοσο νιεμann-pick τυπου a |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090117156A1 (https=) |
| EP (2) | EP3456331B1 (https=) |
| JP (2) | JP5706602B2 (https=) |
| AR (1) | AR059371A1 (https=) |
| BR (1) | BRPI0707590A2 (https=) |
| CY (1) | CY1121380T1 (https=) |
| DK (1) | DK1986661T3 (https=) |
| ES (1) | ES2700048T3 (https=) |
| HU (1) | HUE041928T2 (https=) |
| IL (2) | IL193165B (https=) |
| LT (1) | LT1986661T (https=) |
| MX (3) | MX360595B (https=) |
| PL (1) | PL1986661T3 (https=) |
| PT (1) | PT1986661T (https=) |
| SI (1) | SI1986661T1 (https=) |
| WO (1) | WO2007092563A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1879623T3 (pl) | 2005-05-02 | 2013-03-29 | Genzyme Corp | Terapia genowa zaburzeń rdzenia kręgowego |
| EP1879624B1 (en) | 2005-05-02 | 2011-09-21 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
| PL3252161T3 (pl) | 2007-06-06 | 2022-03-07 | Genzyme Corporation | Terapia genowa dla lizosomalnych chorób spichrzeniowych |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| EP2826860B1 (en) * | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| WO2012145646A1 (en) * | 2011-04-20 | 2012-10-26 | Miguel Sena-Esteves | Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis |
| CN105377039A (zh) * | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| AU2015335923B2 (en) | 2014-10-21 | 2021-04-29 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| EP3270944B1 (en) * | 2015-03-17 | 2019-10-23 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for fviii and fix |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| IL305449B2 (en) | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous type ii diabetes |
| TW201819398A (zh) | 2016-09-28 | 2018-06-01 | 美商寇峇有限公司 | 治療性肽 |
| EP3526333A4 (en) | 2016-10-13 | 2020-07-29 | University of Massachusetts | AAV CAPSIDE DESIGNS |
| EP3534892A4 (en) * | 2016-11-04 | 2020-05-27 | The Children's Hospital of Philadelphia | GENE TRANSFER COMPOSITIONS, METHODS AND USE FOR TREATING NEURODEGENERATIVE DISEASES |
| WO2018156892A1 (en) | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
| US12116577B2 (en) | 2017-06-20 | 2024-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditions |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| US20210363191A1 (en) | 2018-04-03 | 2021-11-25 | Stridebio, Inc. | Antibody-evading virus vectors |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| EP3917944A1 (en) | 2019-01-28 | 2021-12-08 | Cohbar Inc. | Therapeutic peptides |
| BR112021018776A2 (pt) | 2019-03-21 | 2021-11-30 | Stridebio Inc | Vetores de vírus adenoassociado recombinante |
| MX2021012578A (es) * | 2019-04-24 | 2021-12-10 | Univ Oregon Health & Science | Secuencia promotora y productos y usos relacionados de la misma. |
| KR20220083714A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터 |
| KR20230031329A (ko) * | 2020-06-30 | 2023-03-07 | 칠드런스 내셔널 메디컬 센터 | 골격 근섬유 복구를 개선하기 위한 재조합 인간 산성 스핑고미엘리나제의 용도 |
| EP4200408A1 (en) | 2020-08-19 | 2023-06-28 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of rett syndrome |
| JP2024506860A (ja) * | 2021-02-01 | 2024-02-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ニーマンピック病ａ型を治療するための組成物及び方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| DE3424893A1 (de) | 1984-07-06 | 1986-02-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches silberhalogenidaufzeichnungsmaterial |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US6114114A (en) | 1992-07-17 | 2000-09-05 | Incyte Pharmaceuticals, Inc. | Comparative gene transcript analysis |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| CA2187626C (en) | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| AU1775901A (en) * | 1999-11-17 | 2001-05-30 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| CA2400634A1 (en) * | 2000-02-17 | 2001-08-23 | Chester Li | Genetic modification of the lung as a portal for gene delivery |
| US20010031741A1 (en) * | 2000-02-17 | 2001-10-18 | Robin Ziegler | Methods for treatment of lysosomal storage diseases |
| US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| CA2361462A1 (en) * | 2001-11-07 | 2003-05-08 | Katherine A. High | Induction of tolerance to a therapeutic polypeptide |
| WO2003105750A2 (en) * | 2002-06-14 | 2003-12-24 | Yeda Research And Development Co. Ltd | Antigen-presenting cells for neuroprotection and nerve regeneration |
| AU2003265855A1 (en) * | 2002-08-28 | 2004-03-19 | University Of Florida | Modified aav |
| US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
-
2007
- 2007-02-08 JP JP2008554342A patent/JP5706602B2/ja active Active
- 2007-02-08 WO PCT/US2007/003388 patent/WO2007092563A2/en not_active Ceased
- 2007-02-08 EP EP18190420.2A patent/EP3456331B1/en active Active
- 2007-02-08 DK DK07763560.5T patent/DK1986661T3/da active
- 2007-02-08 PT PT07763560T patent/PT1986661T/pt unknown
- 2007-02-08 PL PL07763560T patent/PL1986661T3/pl unknown
- 2007-02-08 BR BRPI0707590-1A patent/BRPI0707590A2/pt not_active IP Right Cessation
- 2007-02-08 MX MX2014005624A patent/MX360595B/es unknown
- 2007-02-08 AR ARP070100528A patent/AR059371A1/es not_active Application Discontinuation
- 2007-02-08 HU HUE07763560A patent/HUE041928T2/hu unknown
- 2007-02-08 EP EP07763560.5A patent/EP1986661B1/en active Active
- 2007-02-08 LT LTEP07763560.5T patent/LT1986661T/lt unknown
- 2007-02-08 ES ES07763560T patent/ES2700048T3/es active Active
- 2007-02-08 SI SI200732075T patent/SI1986661T1/sl unknown
-
2008
- 2008-07-31 IL IL193165A patent/IL193165B/en not_active IP Right Cessation
- 2008-08-07 MX MX2018013684A patent/MX2018013684A/es unknown
- 2008-08-07 MX MX2018008355A patent/MX2018008355A/es unknown
- 2008-08-07 US US12/187,844 patent/US20090117156A1/en not_active Abandoned
-
2013
- 2013-04-25 JP JP2013092907A patent/JP5881641B2/ja active Active
-
2018
- 2018-04-09 IL IL258587A patent/IL258587A/en unknown
- 2018-11-28 CY CY20181101265T patent/CY1121380T1/el unknown
-
2019
- 2019-08-19 US US16/544,735 patent/US20200080066A1/en not_active Abandoned
-
2023
- 2023-03-08 US US18/119,201 patent/US20230287366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1986661T3 (da) | 2019-01-02 |
| IL193165B (en) | 2018-04-30 |
| AR059371A1 (es) | 2008-03-26 |
| JP2009526067A (ja) | 2009-07-16 |
| US20230287366A1 (en) | 2023-09-14 |
| EP1986661A2 (en) | 2008-11-05 |
| JP2013166777A (ja) | 2013-08-29 |
| US20090117156A1 (en) | 2009-05-07 |
| EP3456331A1 (en) | 2019-03-20 |
| MX360595B (es) | 2018-11-09 |
| LT1986661T (lt) | 2018-12-10 |
| BRPI0707590A2 (pt) | 2011-05-10 |
| MX2018013684A (es) | 2021-06-15 |
| EP1986661A4 (en) | 2012-04-25 |
| JP5881641B2 (ja) | 2016-03-09 |
| IL258587A (en) | 2018-06-28 |
| PT1986661T (pt) | 2018-12-05 |
| PL1986661T3 (pl) | 2019-02-28 |
| WO2007092563A3 (en) | 2007-11-22 |
| US20200080066A1 (en) | 2020-03-12 |
| SI1986661T1 (sl) | 2018-12-31 |
| MX2018008355A (es) | 2021-06-15 |
| WO2007092563A2 (en) | 2007-08-16 |
| JP5706602B2 (ja) | 2015-04-22 |
| HUE041928T2 (hu) | 2019-06-28 |
| EP3456331B1 (en) | 2021-05-26 |
| ES2700048T3 (es) | 2019-02-13 |
| EP1986661B1 (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121380T1 (el) | Γονιδιακη θεραπεια για τη νοσο νιεμann-pick τυπου a | |
| CY1123901T1 (el) | Φαρμακευτικη συνθεση και χορηγησεις αυτης | |
| EA201391756A1 (ru) | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами | |
| CY1111269T1 (el) | Ρυθμιστες βενζιμιδαζολης του vr1 | |
| CL2012002423A1 (es) | Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil. | |
| EA201391521A1 (ru) | Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании | |
| CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| NO20090780L (no) | Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser | |
| CL2017003288A1 (es) | Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214) | |
| CY1119166T1 (el) | Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| CY1113177T1 (el) | Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων | |
| EA201500923A1 (ru) | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с | |
| EA202090053A3 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| AR087091A1 (es) | Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso | |
| TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| CR20120018A (es) | Profármacos que comprenden un conjugado de insulina-conector | |
| EA201390840A1 (ru) | Полициклический lpaантагонист и его применение | |
| AR074227A1 (es) | Anticuerpos contra il-6 y uso de los mismos | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| BR112015010779A2 (pt) | moduladores de di-hidropirazol gpr40 | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) |